News

Hosted on MSN19d
Biohaven to present 13 abstracts at 2025 AAN annual meeting
TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, “We are excited to highlight our clinical and scientific ...
Yahoo Finance21d
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation. Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, "We are excited to highlight our clinical and scientific ...